Clearside Biomedical Inc. (CLSD) Has Soared To A New High On Study Results

Clearside Biomedical Inc. (CLSD) announced Monday morning that its Phase 3 study of suprachoroidal CLS-TA, in patients with macular edema associated with non-infectious uveitis, met its primary endpoint and all of its key secondary endpoints.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>